

Special Issue

Recent Research of Hairy Cell Leukemia

Message from the Guest Editor

Hairy cell leukemia is a very rare and well-defined entity that is characterized by atypical lymphoid cells with hairy projections in the peripheral blood, spleen, and/or liver. HCL represents 0.7% of all malignant hematological disorders and 3.0% of all leukemia. Based on the estimated 2019 leukemia incidence of 61,780 in the United States, approximately 1240 new HCL cases are expected per year. In 2013, the estimated number of new cases was 1417 cases in the European Union, and it was 304 new cases in France in 2018.

The few available population-based studies are limited. Issues related to environmental and exposure risk factors in HCL are unclear. The protective role of cigarette smoking was demonstrated, and an increased risk in people who live or work on a farm was established. However, the etiology of HCL remains unknown. The risk of secondary cancer is high, especially that of another hematologic disorder. For further reading, please follow the link to the Special Issue Website at:

https://www.mdpi.com/journal/cancers/special_issues/Hairy_Cell_Leukemia

Guest Editor

Prof. Dr. Xavier Troussard
Laboratoire d'Hématologie, CHU de Caen, F-14033 Caen, France

Deadline for manuscript submissions

closed (31 December 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/si/80673](https://www.mdpi.com/si/80673)

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://www.mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)